Aims To summarize the totality of evidence validating the Predicting Bleeding Complications
in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy …

Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …

Background Optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing
complex percutaneous coronary intervention (PCI) remains under investigation. Our aim is …

Current research on cardiovascular prevention predominantly focuses on risk-stratification
and management of patients with coronary artery disease (CAD) to optimize their prognosis …

The control of cardiovascular risk factors, the promotion of a healthy lifestyle, and
antithrombotic therapy are the cornerstones of secondary prevention after acute coronary …

The amount of coronary calcium strongly correlates with the degree of atherosclerosis and,
therefore, with the rate of future cardiac events. Calcified coronary lesions still represent a …

The key role played by platelets in the atherosclerosis physiopathology, especially in the
acute setting, is ascertained: they are the main actors during thrombus formation and, thus …

Risk-based antithrombotic strategies after percutaneous coronary intervention (PCI). Dual
antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is indicated for …

Vitamin D is rightly recognized as an essential key factor in the regulation of calcium and
phosphate homeostasis, affecting primary adequate bone mineralization. In the last …

Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …